Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma
NCT04428047 · UNICANCER · PHASE2 · terminated · last registry update 2022-04-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision following information on cases of hyperprogression and early toxicities with bintrafusp alfa in other studies” | – | Registry record, UNICANCER |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD274 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-03-21Results posted on the registry: City of Hope Medical Center, Atezolizumab + Capecitabine (NCT03853707)
- 2023-03-02Phase 3 first posted: Sir Run Run Shaw Hospital, Envafolimab (NCT05752136)
- 2023-01-18Phase 3 first posted: AstraZeneca, Datopotamab deruxtecan + Durvalumab (NCT05687266)
- 2022-12-12Results posted on the registry: AstraZeneca, Durvalumab + Placebo for Olaparib (NCT03775486)
- 2022-11-29Phase 3 first posted: AstraZeneca, Dato-DXd + Durvalumab (NCT05629585)
- 2022-08-01Phase 3 first posted: Georgetown University, Atezolizumab + Bevacizumab (NCT05482516)
- 2022-04-08Phase 3 first posted: InSightec, Pembrolizumab + Atezolizumab (NCT05317858)
- 2022-03-31Phase 3 first posted: AstraZeneca, Durvalumab (NCT05303532)
- 2022-03-31Phase 3 first posted: AstraZeneca, Tremelimumab + Durvalumab (NCT05301842)
- 2022-03-28Phase 3 first posted: Merck Sharp & Dohme LLC, pembrolizumab/vibostolimab + durvalumab (NCT05298423)
- 2022-02-24Phase 3 first posted: Leiden University Medical Center, Chemotherapy + Durvalumab (NCT05255653)
- 2022-02-09Results posted on the registry: Canadian Cancer Trials Group, Durvalumab + Tremelimumab (NCT03057106)
- 2022-02-03Phase 3 first posted: AstraZeneca, Durvalumab + Oleclumab (NCT05221840)
- 2022-01-27Phase 3 first posted: AstraZeneca, Durvalumab + Domvanalimab (NCT05211895)
- 2021-12-27Phase 3 first posted: Hoffmann-La Roche, Alectinib + Entrectinib (NCT05170204)
- 2021-11-09Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Bevacizumab (NCT05112965)
- 2021-10-26Phase 3 first posted: National Cancer Institute (NCI), Avelumab + Cabozantinib S-malate (NCT05092958)
- 2021-10-25Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Lurbinectedin (NCT05091567)
- 2021-10-01Phase 3 first posted: National Cancer Institute (NCI), Atezolizumab + Bevacizumab (NCT05063552)
- 2021-09-28Phase 3 first posted: National Cancer Institute (NCI), Atezolizumab + Carboplatin (NCT05058651)
- 2021-09-28Phase 3 first posted: Pfizer, Avelumab + Lorlatanib (NCT05059522)
- 2021-09-17Phase 3 first posted: Hoffmann-La Roche, Atezolizumab (NCT05047250)
- 2021-09-13Phase 3 first posted: AstraZeneca, savolitinib + durvalumab (NCT05043090)
- 2021-05-05Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Trastuzumab Emtansine (NCT04873362)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision